Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 6826 to 6840 of 7707 results

  1. DHT pilot: DECODE decision support system for the identification of dementia (Discontinued)

    Discontinued [GID-MT536]

    Medical technologies guidance
    Discontinued

  2. Ribociclib in combination with endocrine therapy and goserelin for previously untreated hormone receptor-positive, HER2-negative advanced breast cancer in premenopausal women (ID1307)

    In development [GID-TA10261] Expected publication date: TBC

    Technology appraisal guidance
    In development

  3. Rheumatoid arthritis - adalimumab, etanercept and infliximab (sequential use) [ID18]

    Discontinued [GID-TAG393]

    Technology appraisal guidance
    Discontinued

  4. Phentermine with topiramate for the treatment of obesity and overweight [ID543]

    Discontinued [GID-TAG439]

    Technology appraisal guidance
    Discontinued

  5. Empagliflozin for reducing the risk of cardiovascular events in type 2 diabetes [ID1037]

    Discontinued [GID-TA10177]

    Technology appraisal guidance
    Discontinued

  6. Pembrolizumab for untreated PD-L1 positive non-small-cell lung cancer with at least 1% tumour proportion score [ID1247]

    Discontinued [GID-TA10271]

    Technology appraisal guidance
    Discontinued

  7. Lapatinib for breast cancer (first line use in advanced or metastatic hormone-sensitive breast cancer) [ID115]

    Discontinued [GID-TAG404]

    Technology appraisal guidance
    Discontinued

  8. Psoriasis - briakinumab (suspended) [ID65]

    Discontinued [GID-TAG412]

    Technology appraisal guidance
    Discontinued

  9. Avelumab for previously treated platinum-resistant ovarian cancer ID1497

    In development [GID-TA10404] Expected publication date: TBC

    Technology appraisal guidance
    In development

  10. Hepatitis B (adults) - entecavir and tenofovir disoproxil fumarate [ID111]

    Discontinued [GID-TAG414]

    Technology appraisal guidance
    Discontinued

  11. Nivolumab with ipilimumab for untreated recurrent or metastatic squamous cell cancer of the head and neck cancer [ID1429]

    Discontinued [GID-TA10512]

    Technology appraisal guidance
    Discontinued

  12. Veliparib in combination for treating BRCA-positive, HER2-negative breast advanced cancer [ID1404]

    Discontinued [GID-TA10327]

    Technology appraisal guidance
    Discontinued

  13. Nivolumab for small-cell lung cancer after platinum-based chemotherapy [ID1126]

    Discontinued [GID-TA10158]

    Technology appraisal guidance
    Discontinued

  14. Nintedanib for untreated malignant pleural mesothelioma [ID1424]

    Discontinued [GID-TA10359]

    Technology appraisal guidance
    Discontinued

  15. Pembrolizumab for previously treated metastatic triple negative breast cancer [ID1246]

    Discontinued [GID-TA10295]

    Technology appraisal guidance
    Discontinued